Small molecule anti-cancer therapeutic - U.S. Precision Medicine
Latest Information Update: 26 Jul 2024
At a glance
- Originator U.S. Precision Medicine
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 21 May 2024 Small molecule anti-cancer therapeutic - U.S. Precision Medicine is available for licensing as of 21 May 2024. https://www.usprecisionmedicine.com/
- 21 May 2024 U.S Precision Medicine has patent protection for small molecule anti-cancer therapeutic
- 21 May 2024 Preclinical trials in Solid tumours in USA (unspecified route) before May 2024